Premium
Evaluation and Comparison of the Adverse Effects of Streptokinase and Alteplase
Author(s) -
Tisdale James E.,
Colucci Robert D.,
Ujhelyi Michael R.,
Kluger Jeffrey,
Fieldman Arnold,
Chow Moses S. S.
Publication year - 1992
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1992.tb04486.x
Subject(s) - streptokinase , medicine , myocardial infarction , adverse effect , dose , anesthesia
The frequency and severity of adverse effects resulting from the administration of streptokinase and alteplase were determined in 126 consecutive patients who received standard dosages of these agents for the treatment of acute myocardial infarction. Evaluation was based on patient assessment by nursing staff, physicians, and the investigators before, during, and after thrombolytic administration. Overall, adverse effects occurred in 15 (41.7%) of 36 patients receiving streptokinase and 12 (13.3%) of 90 receiving alteplase (p=0.001). No major bleeding or neurologic events were documented. Minor bleeding occurred in 13.9% and 7.8% of streptokinase and alteplase recipients, respectively (p=0.47), and hypotension in 8 (22.2%) and 5 (5.6%), respectively (p=0.01). The frequency of hypotension associated with streptokinase was significantly higher than that with alteplase. Thrombolytic‐induced hypotension was easily managed and was not associated with sequelae.